NASDAQ · SGMO
Healthcare · Biotechnology
$0.18
Up+$0.00 (+0.00%)
Updated Aug 15, 2026, 5:00 AM
SID Score
3.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
SGMO does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning SGMO.
SGMO research
Company profile and research snapshot.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Feb 10, 2026 | HC Wainwright & Co. | Buy | — |
| Nov 7, 2025 | Barclays | Equal-Weight | — |
| Sep 4, 2025 | HC Wainwright & Co. | Buy | — |
| Jun 24, 2025 | HC Wainwright & Co. | Buy | — |
| May 14, 2025 | Barclays | Overweight | — |
No generated briefing is available yet.
Benzinga · Jun 23, 2026
https://www.sec.gov/ix?doc=/Archives/edgar/data/1001233/000119312526278582/d161847d8k.htm
Finnhub · May 12, 2026
ST-503 nonclinical safety studies evaluating zinc finger repressors regulating expression of the Nav1.7 gene for treatment of small fiber neuropathy Kathleen...
Finnhub · May 12, 2026
Zinc finger fusions and synthetic DNA donor engineering improve the performance of reprogrammed modular integrases at the TRAC locus Jessica E Davis, Friedrich Fauser, Sebastian...
Finnhub · May 12, 2026
Cell segmentation Neuron identification ZFR mRNA detection PRNP mRNA detection Introduction ...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SGMO.
